Avricore Health Corporate Update: Effective Plan, Resources Result in Success
Avricore Health Corporate Update: Effective Plan, Resources Result in Success
VANCOUVER, British Columbia, Nov. 29, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or "Avricore") reports on its third quarter results for 2024 where the Company continues to see rising revenues and profitability.
AVRICORE HEALTH INC.(tsxv:AVCR)(以下简称"公司"或"Avricore")报告了2024年第三季度的业绩,公司继续看到营收和盈利能力持续增长。
- In the nine months ended September 30, 2024, revenue increased by 58% year over year to $3,364,635 and gross profit increased by 84% to $1,290,357.
- In the three months ended September 30, 2024, revenue increased by 25% year over year to $1,195,122 and gross profit increased by 66% to $434,791.
- In the nine months ended September 30, 2024, the Company recorded net profit of $43,494 and a net increase in cash of $503,994.
- 截至2024年9月30日的九个月内,营业收入同比增长58%,达到336,4635美元,毛利润同比增长84%,达到1,290,357美元。
- 截至2024年9月30日的三个月内,营业收入同比增长25%,达到1,195,122美元,毛利润同比增长66%,达到434,791美元。
- 截至2024年9月30日的九个月内,公司录得43494美元的净利润和503994美元的现金净增加。
"The global healthcare landscape is rapidly evolving and HealthTab is uniquely positioned to play a critical role in the future of community-based care," said Hector Bremner, CEO of Avricore. "We are more confident than ever in our path forward as we are actively focused on expanding our market reach, especially the UK, where we see significant opportunities for growth in 2025 and beyond."
"全球医疗保健格局正在迅速发展,而HealthTab在未来基于社区护理中扮演关键角色的定位是独一无二的," Avricore的首席执行官Hector Bremner表示:"我们对前路充满信心,积极致力于扩大我们的市场份额,尤其是在英国,我们看到2025年及以后的增长机会是巨大的。"
GROWTH STRATEGY 2025 AND BEYOND
2025年及之后的增长战略
Recently, the Company announced its strategy to grow HealthTab in the United Kingdom — a decision aligned with the region's robust healthcare market and significant investment in pharmacy-led services. The timing of the Company's strategic efforts is driven by unprecedented UK government investment in UK pharmacy services.
最近,公司宣布了在英国发展HealthTab的战略 — 这个决定与该地区强劲的医疗市场和对药房主导服务的重大投资保持一致。公司战略努力的时间安排是由英国政府在药房服务方面史无前例的投资驱动的。
The NHS has committed £645 million (approx. $1.1 billion CAD) to its Pharmacy First program over 2024, which it hopes will increase access to primary care services, which are currently very strained. The program also seeks to increase the equity of care delivery in communities typically underserved, but need is high with respect to chronic diseases, such as heart disease and diabetes.
英国国民保健服务体系(NHS)已承诺在2024年向其首选药房计划投资64500万英镑(约合11亿加元),希望能够增加对初级保健服务的获取,目前这一领域供需紧张。该计划还旨在增加社区中通常被忽视但慢性疾病需求较高的照料公平性。
Pharmacy-based screening programs have shown strong patient uptake in the UK, as recently the NHS Confederation released their report measuring return on investment (ROI) for healthcare expenditures in October of this year. The report listed community based cardiovascular disease screening and prevention as one of the best ROI's at £7.52 per £1 invested after five years, further stating that "Implementing community pharmacies to aid in the detection of cardiovascular disease provided the quickest return, within one year."
基于药房的筛查计划在英国显示出患者积极参与情况良好。最近,英国国民保健体系联盟发布了一份报告,报告显示今年10月医疗支出的回报率(ROI)。该报告列出了基于社区的心血管疾病筛查与预防作为在五年后每1英镑投资的回报率中最佳之一,为7.52英镑,进一步指出“将社区药房纳入心血管疾病检测是提供最快回报的方式,一年内就能看到成效。”
Currently, the NHS has one of the lowest family doctors to patient ratios it's had in decades, meaning one GP is responsible for almost 2,300 patients on average. However, there are 12,000 pharmacies in the UK, and more than half are participating currently in POCT blood-pressure screening, conducting almost 250,000 screenings per month, demonstrating high amounts of undiagnosed hypertension.
目前,英国国民保健服务体系的家庭医生对患者的比例是数十年来最低的,平均每位全科医生负责近2300名患者。但目前英国有12,000家药房,其中超过一半正在参与POCt血压筛查,每月进行近25万次筛查,显示出高比例的未诊断高血压病例。
This is prescient as just two weeks ago, the NHS announced "shocking" findings of the rapid rise of strokes in people over 50, rising 55% in the last ten years*. The challenge for the industry and the NHS, is that only about 7% of UK pharmacies are profitable**, adding services will not only ensure better access to care for patients and reduce acute and long-term chronic disease costs, but also ensure financial security for these critical healthcare access points. Services, which are currently being accessed at community pharmacies by up to 56 million UK people in the country in an unfunded way***, are clearly a path to financial stability for the pharmacy sector, and the NHS as a whole, given its proven ROI.
这是一个准确的观点,就在两周前,NHS宣布"令人震惊"的发现:50岁以上中风率快速上升,在过去的十年里增长了55%。行业和NHS面临的挑战是,仅有大约7%的英国药房盈利,增加服务不仅可以确保患者更好地获得护理,并降低急性和长期慢性疾病的成本,还能为这些关键的医疗保健接入点确保财务安全。目前,在社区药房以无资金支持的方式向全英国高达5600万人提供服务,显然是药房行业和整个NHS的财务稳定之路,鉴于其经得起考验的回报率。
Because the Company expects devices to be redeployed to new locations in Canada and the UK, management estimates that the Company will not require investment in new devices for the next 12 to 18 months. It also expects cash-on-hand, expected future cash inflows from revenues, and cash savings from redeployment of devices to be sufficient to finance working capital for the next 12 to 18 months.
因为公司预计将设备重新部署到加拿大和英国的新位置,管理层估计公司在未来12至18个月内不需要投资于新设备。公司还期望手头现金、预期未来来自营收的现金流入以及设备重新部署带来的现金节省足以为未来12至18个月的营运资金提供资金。
FINANCIAL SNAPSHOT
财务快照
Sources and Uses of Cash: | Period ended September 30, | |||
2024 | 2023 | |||
$ | $ | |||
Cash provided by operating activities | 657,869 | 412,400 | ||
Cash used in investing activities | (192,975) | (685,896) | ||
Cash provided by financing activities | 39,100 | 42,500 | ||
Cash and Cash Equivalents, closing balance | 780,515 | 389,531 |
现金的来源和用途: | 截至9月30日的期间 | |||
2024 | 2023 | |||
$ | $ | |||
来自经营活动的现金流入 | 657,869 | 412,400 | ||
投资活动使用的现金 | (192,975) | (685,896) | ||
融资活动提供的现金流量 | 39,100 | 为了转换应付账款而发行的股票 | ||
现金及现金等价物,期末余额 | 780,515 | 389,531 |
The following table highlights selected financial data for each of the eight most recent quarters.
以下表格突出显示最近八个季度的部分财务数据。
Quarter Ended | Sep | June | March | Dec | Sep | June | Mar | Dec | ||||||||
2024 | 2024 | 2024 | 2023 | 2023 | 2023 | 2023 | 2022 | |||||||||
$ | $ | |||||||||||||||
Revenue | 1,195,122 | 1,045,206 | 1,124,307 | 1,354,403 | 953,454 | 548,049 | 629,241 | 997,235 | ||||||||
Gross profit | 434,791 | 370,775 | 484,791 | 501,466 | 261,778 | 229,471 | 210,681 | 168,845 | ||||||||
Share-based compensation | 338,089 | 1,598 | 27,464 | 142,765 | 304,328 | 168,518 | 88,001 | 243,000 | ||||||||
Comprehensive income (loss) | (179,065) | 54,022 | 168,537 | 59,584 | (285,062) | (284,225) | (191,512) | (244,789) | ||||||||
Net profit (loss)/share | (0.00) | 0.00 | 0.00 | (0.00) | (0.00) | (0.00) | (0.00) | (0.00) | ||||||||
Total Assets | 3,024,103 | 2,618,384 | 2,798,058 | 2,538,205 | 2,453,136 | 2,143,810 | 2,296,565 | 2,568,983 |
季度结束 | 九月 | 六月 | 三月 | Dec | 九月 | 六月 | Mar | Dec | ||||||||
2024 | 2024 | 2024 | 2023 | 2023 | 2023 | 2023 | 2022 | |||||||||
$ | $ | |||||||||||||||
Revenue | 1,195,122 | 1,045,206 | 1,124,307 | 1,354,403 | 953,454 | 548,049 | 629,241 | 997,235 | ||||||||
毛利润 | 434,791 | 370,775 | 484,791 | 501,466 | 261,778 | 229,471 | 210,681 | 168,845 | ||||||||
基于股份的薪酬 | 338,089 | 1,598 | 27,464 | 142,765 | 304,328 | 168,518 | 88,001 | 243,000 | ||||||||
综合收益(损失) | (179,065) | 54,022 | 168,537 | 59,584 | (285,062) | (284,225) | (191,512) | (244,789) | ||||||||
净利润(亏损)/每股 | (0.00) | 0.00 | 0.00 | (0.00) | (0.00) | (0.00) | (0.00) | (0.00) | ||||||||
总资产 | 3,024,103 | 2,618,384 | 2,798,058 | 2,538,205 | 2,453,136 | 2,143,810 | 2,296,565 | 2,568,983 |
LOOKING AHEAD
展望未来
The Company's activities are focused on delivering on the exciting growth opportunities in front of it. This includes:
公司的活动重点是抓住面前令人兴奋的增长机遇。这包括:
Operational Expansion
运营扩展
Phase I: London and Other High-Priority Regions: Following the North East London (NEL) success, expand to large population areas and a mix of demographics ideal for preventative programs.
第一阶段: 伦敦和其他重点地区:在北东伦敦(NEL)取得成功后,扩展至人口稠密地区和各种人口结构理想的预防计划。
Phase II: National Scaling Through NHS: Once initial targets demonstrate efficacy, work with NHS to incorporate HealthTab as part of a broader roll-out, potentially embedding the cholesterol testing service within the NHS's Pharmacy First protocols nationwide.
第二阶段: 通过NHS进行全国推广:一旦初始目标显示出功效,与NHS合作,将HealthTab纳入更广泛的推广计划,有可能将胆固醇测试服务嵌入到全英国的NHS药房优先协议中。
Marketing and Awareness Campaigns
营销和宣传活动
Public Awareness Campaigns: Launch educational campaigns in pharmacies and through NHS communication channels to raise awareness of cardiovascular disease and the importance of early testing. Highlight the role of HealthTab in this preventive ecosystem.
公共意识活动: 通过药房和英国国民健康服务传播渠道启动教育宣传活动,提高人们对心血管疾病及早期检测的重要性的认识。突出HealthTab在这一预防生态系统中的作用。
Direct-to-Pharmacist Education: Offer training and informational sessions to pharmacists across the UK to familiarize them with HealthTab technology and its benefits. This aligns with NHS goals of empowering community pharmacists as frontline health workers.
面向药剂师的直接教育: 向整个英国的药剂师提供培训和信息会议,使其熟悉HealthTab技术及其好处。这与英国国民健康服务赋予社区药剂师作为一线卫生工作者的目标一致。
Next Milestones:
下一步里程碑:
- Support launch of initial patient testing (Nov-Dec 2024)
- Add new locations (Dec 2024/Jan 2025)
- Complete V1 API to NHS record provider (Dec 2024)
- Add AI insights and support assistant within HealthTab (Q1 2025)
- NHS Review, sets second phase goals (April 2025)
- 支持2024年11月至12月进行初步患者测试启动
- 添加新的地点(2024年12月/2025年1月)
- 完成到全民健康服务提供商的V1 API(2024年12月)
- 在HealthTab内增加人工智能洞见和支持助手(2025年第1季度)
- 全民健康服务评估,制定第二阶段目标(2025年4月)
HEALTHTAB MARKET FAST-FACTS
HEALTHTAb市场快讯
- Point of Care Testing Market to reach $93.21 Billion USD in 2030 (Source)
- Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed (Source)
- Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source)
- Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. (Source)
- There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.
- 预计到2030年将有将近1360万加拿大人患糖尿病或糖尿病前期,其中许多人没有被诊断出来(数据来源)。
- 超过三分之一的美国人,约8800万人,有糖尿病前期(数据来源)。
- 每年有近16万名20岁及以上的加拿大人被诊断为患有心脏病,往往在心脏病发作后才被诊断出来(数据来源)。
- 加拿大有超过10,000家药房,在美国有88,000家药房,英国有将近12,000家药房。
- 关于HealthTab
SOURCES
资源
*
*
**
**
***
***
ABOUT HEALTHTAB
ABOUt HEALTHTAB
HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.
HealthTab网络模型与任何一种药店模型都不同。它赋予权威、值得信赖的药剂师在初级医疗保健中扮演更重要的角色,同时使患者更加掌控自己的健康。它还降低了成本和等待时间,并提供了许多潜在的收入来源,包括设备租赁和耗材、直接获取测试、疾病预防和管理计划、赞助的健康计划、去中心化的临床试验、现实世界数据(RWD)集以及API通过第三方应用程序集成。
The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.
关于Avricore Health Inc.
ABOUT AVRICORE HEALTH INC.
关于AVRICORE HEALTH INC.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab, a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.
Avricore Health Inc.(tsxv:avcr)是一家专注于收购和开发早期技术以推进药店实践和患者护理的药店服务创新者。通过其旗舰产品HealthTab,该公司的全资子公司,其使命是通过在社区药店创建全球最大的快速测试设备网络,使可操作的健康信息更加普遍。
CONTACT:
联系人:
Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
关于前瞻性声明的警示
本新闻稿中所涉及的Avricore Health的期望、计划、意图或策略涉及未来的前瞻性声明,这些前瞻性声明不是事实,涉及一系列风险和不确定性。Avricore Health通常使用“展望”、“将”、“可能”、“将会”、“可能”、“保持”、“计划”、“相信”、“可能”、“预计”、“打算”、“预期”、“估计”、“未来”、“定位”、“潜力”、“项目”、“仍有”、“安排”、“受”、“即将”等表达方式来帮助识别前瞻性声明。在本新闻稿中,前瞻性声明包括关于:完成配售的完成以及预期的时间以及公司对配售所得款项的预期用途;HealthTab平台向药剂师和患者提供的独特功能。前瞻性声明反映Avricore Health管理层当时的期望、信念、假设、估计和预测。在本新闻稿中的前瞻性声明基于Avricore Health在本新闻稿发布之日可获得的信息。相信前瞻性声明在制作时是正确的,但最终可能证明是不正确的。这些声明并不是Avricore Health未来业绩的保证,并受到一些风险、不确定性和其他因素的影响,其中一些因素超出其控制范围,并可能导致实际结果与当前预期有所不同,包括但不限于:未能满足监管要求;市场变化;经济状况可能出现下滑;以及Avricore的公共文件中描述的其他风险因素。这些前瞻性声明仅在发布之日起生效,除非法律要求否则不对其进行公开更新以反映新信息或未来事件或情况的发生。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
TSX创业公司交易所或其监管服务提供商(如TSX创业公司政策中定义的那样)不对本公告的充分性或准确性负责。